Cancer is difficult to treat as every type of cancer is different, and it can further evolve over time. This evolution demands different treatments for different stage of cancer. Non-invasive cancer diagnostic is a process of identifying the cancer conditions with minimal incision in body during diagnosis.
The global non-invasive cancer diagnostic market is expected to show considerable growth during the forecast period. This is attributed to growing cancer cases worldwide, especially breast and lung cancer. In 2013, in the U.S. there were more than 1,660,290 new cases of all type of cancers diagnosed in 2013 (American Cancer Society). Increased healthcare expenditure and increase research and development activities are some of the other factors driving the growth of this market. However factors such as high cost of treatment, and stringent regulatory guidelines are limiting the market growth.
The non-invasive cancer diagnostic market is segmented into three broad categories: by therapeutics, by technology, and by geography. Based on therapeutics, the market is divided into solid tumors, blood cancer, lung cancer, breast cancer, and others. Breast cancer accounted for the largest share of the non-invasive cancer diagnostic market in 2014, owing to rapid increase in the number of breast cancer worldwide. Based on technology the market is segmented into clinical chemistry, immunochemistry/immunoassay, molecular diagnostics, and other clinical instruments.
Geographically, the global non-invasive cancer diagnostic market is segmented into North America, Europe, Asia and Rest of the World (RoW: Latin America, Pacific Countries, and Middle East & Africa). North America is account for the largest share of the non-invasive cancer diagnostic market in 2014. However, Asia is the fastest growing market due to increased funding for cancer research in this region.
Some of the major players in the global non-invasive cancer diagnostic market include Precision Therapeutics, Inc. (U.S.), A&G Pharmaceutical, Inc. (U.S.) Affymetrix Inc. (U.S.), AVIVA Biosciences Corporation (U.S.), BIOVIEW Inc. (U.S.), Laboratory Corporation of America Holdings (LabCorp) (U.S.), Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.), Digene Corporation (U.S.), Gen-Probe Incorporated (U.S.), IVDiagnostics, Inc. (U.S.), and others.
Benchmarking the rapid strategy shifts of the Top 100 companies in the Noninvasive Cancer Diagnostics MarketRequest For Special Pricing